Mary Reilly (academic) explained

Mary Reilly
Birth Place:Belmullet, County Mayo, Ireland
Alma Mater:University College Dublin
Workplaces:National Hospital for Neurology and Neurosurgery
Known For:Inherited neuropathies

Mary M. Reilly FRCP is an Irish neurologist who works at National Hospital for Neurology and Neurosurgery. She studies peripheral neuropathy. She is the President of the Association of British Neurologists.

Early life and education

Reilly studied medicine at University College Dublin, graduating in 1986.[1] [2] She worked for a few years as a neurologist at St. Vincent's University Hospital, before joining Anita Harding at the National Hospital for Neurology and Neurosurgery in 1991.[3] [4] [5] Reilly has spoken of how much she admired her supervisor, and attributes her clinical interests to Harding.[6] Reilly earned her medical doctorate in 1996, focussing on familial amyloid polyneuropathy.[7] [8] She completed her neurological training at Royal Free Hospital and Guy's Hospital, training with P. K. Thomas and Richard Hughes.[9]

Career

At the National Hospital for Neurology and Neurosurgery Reilly specialises in inherited neuropathies.[10] [11] She was made consultant neurologist in 1998 and a Fellow of the Royal College of Physicians in 2002. She began to study neuromuscular disease, [12] in particular Charcot–Marie–Tooth disease.[13] [14] In 2004, she found that Vitamin C could be used to improve symptoms in mouse models of CMT1A (Charcot–Marie–Tooth disease type 1A).[15] She established a randomized controlled trial with colleagues in Italy to evaluate the efficacy of Vitamin C on CMT1A. The UK part of the trial consisted of 50 participants, and found that whilst Vitamin C is safe, it does not slow the progression of the disease. Although the trial was not a success, it developed new neuropathy outcome measures. Her research includes the identification of genes such as BICD2 and methionyl-tRNA synthetase (MARS);[16] [17] she has already conducted functional analysis of IGHMBP2.[18]

Reilly works with Muscular Dystrophy UK on muscle-wasting conditions.[19] She has also worked on new biomarkers for disease progression.[20] CMT parents suffer from damaged motor nerves, which results in muscles weakening, and ultimately allows fat to accumulate in muscles; MRI outcome measures could monitor intramuscular fat accumulation, and detect muscle water changes that preceded fat accumulation.[21] Reilly identified that calf muscle fat friction maps are an outcome measure in patients with CMT1A, with calf muscle fat increased significantly in patients with CMT1A[22] She received a $1,000,000 grant from the Muscular Dystrophy Association to evaluate MRI protocols for monitoring changes in muscles from CMT.[23] [21]

In 2010 Reilly was appointed Professor of Clinical Neurology at University College London.[24] She leads the Division of Clinical Neurology and Medical Research Council Centre for Neuromuscular Diseases.[25] With the MRC Centre for Neuromuscular Diseases and Muscular Dystrophy UK, Reilly runs an annual translational neuromuscular diseases meeting, which includes a patient day to discuss inherited neuropathies. Along with CMT, Reilly has worked on hereditary sensory and autonomic neuropathies and carpal tunnel syndrome in inherited neuropathies.[26]

Reilly contributed to the 2013 Handbook of Clinical Neurology, [27] and wrote a chapter for the 2016 Springer Publishing collection Neuromuscular Disease: Case Studies from Queen Square.[28] Reilly has served as President of the British Peripheral Nerve Society and the International Peripheral Nerve Society.[29] In 2015 she was appointed President-elect of the Association of British Neurologists. She became the first woman to take the role in 2017.

Notes and References

  1. Web site: TREAT-NMD : Mary Reilly. www.treat-nmd.eu. 2019-01-23.
  2. Web site: May 2017. UCD School of Medicine & Medical Science. 2019-01-23.
  3. Web site: Professor Mary Reilly is elected to be the first female President of the Association of British Neurologists in 83 years. UCL. 2015-03-24. UCL Queen Square Institute of Neurology. 2019-01-23.
  4. Web site: May 2017. UCD School of Medicine & Medical Science. 2019-01-23.
  5. Reilly. Mary M.. King. Rosalind H. M.. 1993. Familial Amyloid Polyneuropathy. Brain Pathology. 3. 2. 165–176. 10.1111/j.1750-3639.1993.tb00741.x. 8293178. 22403075 . 1750-3639. free.
  6. Web site: Remembering my first boss, the great Clinical Neurologist Anita Harding, on International Women's…. Cummins. Stephen. 2018-03-08. Medium. 2019-01-23.
  7. Web site: Professor Mary M. Reilly Biography. RCP. 2019-01-23.
  8. Reilly. M.M.. Adams. D.. Booth. D.R.. Davis. M.B.. Said. G.. Laubriat-Bianchin. M.. Pepys. M.B.. Thomas. P.K.. Harding. A.E.. 36930164. 1996. Transthyretin gene analysis in European patients with suspected familial amyloid polyneuropathy. Neuromuscular Disorders. 6. 849–56. 10.1016/0960-8966(96)88834-1. 7655883. 0960-8966.
  9. Web site: Prof. Mary M Reilly, UK RE-ACT Congress. www.react-congress.org. 2019-01-23.
  10. Web site: Iris View Profile. iris.ucl.ac.uk. 2019-01-23.
  11. Reilly. Mary M.. 2009-04-01. Classification and diagnosis of the inherited neuropathies. Annals of Indian Academy of Neurology. 12. 2. 80–8. 10.4103/0972-2327.53075. 0972-2327. 20142852. 2812746 . free .
  12. Hanna. Michael G.. Reilly. Mary M.. 2002-12-01. Genetic neuromuscular disease. Journal of Neurology, Neurosurgery & Psychiatry. 73. suppl 2. ii12–ii21. 10.1136/jnnp.73.suppl_2.ii12. 0022-3050. 12536154. 1765608.
  13. Reilly. Mary M.. Evans. Matthew R. B.. Rossor. Alexander M.. 2015-06-01. A practical approach to the genetic neuropathies. Practical Neurology. 15. 3. 187–198. 10.1136/practneurol-2015-001095. 1474-7758. 25898997. free.
  14. Reilly. Mary M.. Murphy. Sinéad M.. Laurá. Matilde. 2011. Charcot-Marie-Tooth disease. Journal of the Peripheral Nervous System. 16. 1. 1–14. 10.1111/j.1529-8027.2011.00324.x. 21504497. 19868015 . 1529-8027. free.
  15. Web site: First clinical trial for Charcot Marie Tooth Disease. www.musculardystrophyuk.org. 2019-01-23.
  16. Consortium (INC). Inherited Neuropathy. Züchner. Stephan. Reilly. Mary M.. Antonellis. Anthony. Yang. Xiang-Lei. Speziani. Fiorella. Hadjivassilious. Marios. Yo-Tsen. Liu. Guo. Min. 2013-11-01. Exome sequencing identifies a significant variant in methionyl-tRNA synthetase (MARS) in a family with late-onset CMT2. J Neurol Neurosurg Psychiatry. 84. 11. 1247–1249. 10.1136/jnnp-2013-305049. 0022-3050. 3796032. 23729695.
  17. Oates. Emily C.. Rossor. Alexander M.. Hafezparast. Majid. Gonzalez. Michael. Speziani. Fiorella. MacArthur. Daniel G.. Lek. Monkol. Cottenie. Ellen. Scoto. Mariacristina. 2013-06-06. Mutations in BICD2 Cause Dominant Congenital Spinal Muscular Atrophy and Hereditary Spastic Paraplegia. American Journal of Human Genetics. 92. 6. 965–973. 10.1016/j.ajhg.2013.04.018. 0002-9297. 3675232. 23664120.
  18. Cottenie. Ellen. Kochanski. Andrzej. Jordanova. Albena. Bansagi. Boglarka. Zimon. Magdalena. Horga. Alejandro. Jaunmuktane. Zane. Saveri. Paola. Rasic. Vedrana Milic. 2014-11-06. Truncating and Missense Mutations in IGHMBP2 Cause Charcot-Marie Tooth Disease Type 2. American Journal of Human Genetics. 95. 5. 590–601. 10.1016/j.ajhg.2014.10.002. 0002-9297. 4225647. 25439726.
  19. Web site: Working in partnership - Muscular Dystrophy UK. www.musculardystrophyuk.org. 2019-01-23.
  20. Morrow. Jasper M. Sinclair. Christopher D J. Fischmann. Arne. Machado. Pedro M. Reilly. Mary M. Yousry. Tarek A. Thornton. John S. Hanna. Michael G. January 2016. MRI biomarker assessment of neuromuscular disease progression: a prospective observational cohort study. The Lancet. Neurology. 15. 1. 65–77. 10.1016/S1474-4422(15)00242-2. 1474-4422. 4672173. 26549782.
  21. Web site: Critical Biomarker Development for CMT Receives $1 Million Boost from MDA. Staff. M. D. A.. 2018-07-09. MDA. 2019-01-23.
  22. Reilly. Mary M.. Shy. Michael E.. Thornton. John S.. Nopoulos. Peggy. Hanna. Michael G.. Yousry. Tarek A.. Shah. Sachit. Thedens. Daniel. Sinclair. Christopher D. J.. 2018-09-18. Validation of MRC Centre MRI calf muscle fat fraction protocol as an outcome measure in CMT1A. Neurology. 91. 12. e1125–e1129. 10.1212/WNL.0000000000006214. 0028-3878. 30120135. 6161551.
  23. Web site: MDA Funds Development of a Critical Biomarker for Charcot Marie Tooth Disease. 2018-07-09. Muscular Dystrophy Association. 2019-01-23.
  24. Web site: Mary Reilly, MD, FRCP, FRCPI Neuropathy Commons. neuropathycommons.org. 2019-01-23.
  25. Web site: Neuromuscular disease. www.uclh.nhs.uk. 2019-01-23.
  26. Web site: Mary M. Reilly - Head, Professor, Consultant of Neurology in London, England, United Kingdom eMedEvents. www.emedevents.com. 2019-01-23.
  27. Book: Murphy. Sinéad M.. Chapter 12 - DNA testing in hereditary neuropathies. 2013-01-01. Handbook of Clinical Neurology. 115. 213–232. Said. Gérard. Peripheral Nerve Disorders. Elsevier. Laurá. Matilde. Reilly. Mary M.. Krarup. Christian. 10.1016/B978-0-444-52902-2.00012-6. 23931782. DNA testing in hereditary neuropathies. 9780444529022.
  28. Book: 2017. Manji. Hadi. Turner. Chris. Evans. Matthew R. B.. Neuromuscular Disease. 10.1007/978-1-4471-2389-7. 978-1-4471-2388-0.
  29. Web site: Interview with Mary Reilly - President of the Peripheral Nerve society (PNS). eanpages - News Blog of the European Academy of Neurology. 7 July 2017 . 2019-01-23.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Mary Reilly (academic)".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.